Patents by Inventor David Gailani
David Gailani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10577428Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: July 30, 2018Date of Patent: March 3, 2020Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20180355057Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 30, 2018Publication date: December 13, 2018Applicants: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20170204195Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 27, 2017Publication date: July 20, 2017Applicants: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 9637550Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: December 12, 2014Date of Patent: May 2, 2017Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Patent number: 9636399Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: July 27, 2015Date of Patent: May 2, 2017Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 9574013Abstract: Provided are antibodies that selectively bind to and inhibit activation of coagulation factor XII. Methods of treatment employing these antibodies are described herein.Type: GrantFiled: December 6, 2013Date of Patent: February 21, 2017Assignees: VANDERBILT UNIVERSITY, ARONORA, INC., OREGON HEALTH & SCIENCE UNIVERSITYInventors: Andras Gruber, David Gailani, Philberta Leung, Anton Matafonov
-
Publication number: 20150322163Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 27, 2015Publication date: November 12, 2015Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20150315292Abstract: Provided are antibodies that selectively bind to and inhibit activation of coagulation factor XII. Methods of treatment employing these antibodies are described herein.Type: ApplicationFiled: December 6, 2013Publication date: November 5, 2015Inventors: Andras GRUBER, David GAILANI, Philberta LEUNG, Anton MATAFONOV
-
Patent number: 9125895Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: April 1, 2014Date of Patent: September 8, 2015Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20150093395Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: ApplicationFiled: December 12, 2014Publication date: April 2, 2015Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Patent number: 8940883Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: January 31, 2013Date of Patent: January 27, 2015Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20140322219Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 1, 2014Publication date: October 30, 2014Applicants: Vanderbilt University, Oregon Health & Science UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 8399648Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: April 13, 2012Date of Patent: March 19, 2013Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 8388959Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: December 18, 2009Date of Patent: March 5, 2013Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20120276112Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 13, 2012Publication date: November 1, 2012Inventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 8236316Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: November 21, 2008Date of Patent: August 7, 2012Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20110250207Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: ApplicationFiled: December 18, 2009Publication date: October 13, 2011Inventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20110020349Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 21, 2008Publication date: January 27, 2011Inventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani